Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• The endocannabinoid system is implicated in mood regulation and is a potential therapeutic target for depression.
• Electroconvulsive shock (ECS) is an effective treatment for severe depression, but its neurobiological mechanisms are not fully understood.

Purpose of the Study:

• To investigate the effects of single and repeated electroconvulsive shock (ECS) on the endocannabinoid system in specific brain regions.
• To determine how ECS influences endocannabinoid levels, CB(1) receptor binding, and CB(1) receptor-mediated signaling.

Main Methods:

• Assessed endocannabinoid content (anandamide), CB(1) receptor binding parameters (affinity and density), and CB(1) receptor-mediated G-protein activation using [(35)S]GTPgammaS binding assays.
• Examined these parameters in the prefrontal cortex, hippocampus, hypothalamus, and amygdala following single and 10 daily ECS sessions.

Main Results:

• A single ECS session reduced CB(1) receptor binding affinity across regions and decreased anandamide levels in the prefrontal cortex and hippocampus.
• Repeated ECS (10 sessions) maintained reduced anandamide levels and fatty acid amide hydrolase (FAAH) activity in the prefrontal cortex.
• Repeated ECS led to decreased CB(1) receptor density in the prefrontal cortex but enhanced CB(1) receptor-mediated signaling sensitivity in the amygdala.

Conclusions:

• ECS treatment induces region-specific alterations in the endocannabinoid system, with cortical down-regulation and subcortical up-regulation of activity.
• These findings highlight the complex and regionally dependent role of the endocannabinoid system in the neurobiology of affective disorders and ECS treatment response.